Public Citizen targets Abbott’s Cylert

Share this article:

Public Citizen urged the FDA yesterday to remove Abbott Laboratories' 30-year-old attention deficit drug Cylert from the market because of its effects on the liver.
Public Citizen charged that Cylert had caused 21 cases of liver failure, including 13 cases that had been fatal or had required transplants. The petition to the FDA argues that at least 193 patients have suffered serious consequences from the drug.
Abbott vice president of corporate communications Melissa Brotz told the Reuters news service that Abbott had already decided to discontinue the drug due to slumping sales of the brand. 
"We're in the process of discontinuing it . . . but that's because of declining usage and sales because there are generics available," Brotz said.
Brotz told Reuters it anticipated sales of the drug this year to be less than $1 million.
Copycat versions of the drug are sold by generic-drug makers.
Cylert was approved to treat attention deficit hyperactivity disorder in 1975. Last year, 117,000 prescriptions for the drug were filled in the U.S., according to Public Citizen.
The petition comes a wee after the FDA denied a petition from the consumer group asking for a ban on AstraZeneca's cholesterol-lowering drug Crestor.

 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.